Clinical

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.

Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Governor Kathy Hochul proposed this week that New York become the first state to require health systems to implement cyber defenses; a new report from the World Health Organization and the CDC highlighted a staggering rise in measles cases and deaths in 2022; a study published this week claimed that more than a tenth of fecal immunochemical tests used for routine colorectal cancer screening could not be processed by labs.

Plasma ceramides and sphingomyelins with palmitic acid were linked to a 34% and 37% increased risk of sudden cardiac death (SCD) per higher SD of log sphingolipid levels, respectively.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.

The tool assesses the risk of heart attack, stroke, and, for the first time, heart failure, offering a more comprehensive perspective on cardiovascular health.

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.

The CDC has published updated recommendations for the postexposure prevention and treatment of Bacillus anthracis (anthrax) infection; the FDA has granted marketing approval to an at-home chlamydia and gonorrhea test; lawmakers and Veterans Affairs officials acknowledge the potential for psychedelic drugs to treat veterans’ mental health conditions and prevent suicide.

According to researchers, the most prevalent risk factors in children with type 1 spinal muscular atrophy (SMA) are hypercalciuria and elevated urine specific gravity.

With improved survival becoming more common among individuals who have Duchenne muscular dystrophy (DMD), cardiomyopathy is also increasing in prevalence among this population.

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.

Heart failure treatment strategies are emphasized based off recent clinical trial data.

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.

Male adolescent and young adult patients were found to have an increased risk of keratoconus if they had attention-deficit/hyperactivity disorder (ADHD), regardless of confounders.

Patients with chronic obstructive pulmonary disease (COPD) who were from minority ethnic backgrounds were found to have lower adherence to treatment interventions compared with the general population.

Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.

New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs).

Patients who have HIV and are using antiretroviral therapy (ART) did not have adverse outcomes when using nivolumab for cancer treatment.

To combat C difficile, Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy, noted that awareness and innovation must continue to increase.